Brazil Fines Pharma Cartel Over Buscopan Ingredient
Brazil's competition authority sanctioned four drugmakers and three executives after a five-year probe into a cartel that operated for roughly three decades.
Updated on Nov. 4, 2026 in Drug Crime
Brazil's competition regulator CADE sanctioned Alchem International, Alkaloids of India, Alkaloids of Australia, and Vital Laboratories for participating in a cartel covering production and sale of an ingredient used to make Buscopan. Christopher Kenneth Joyce, Rajiv Bajaj, and Stefan Bertram were also sanctioned, with total fines exceeding 17 million reais (over $3 million).
Why it matters
The cartel's effects were felt in Brazil, making the case a notable enforcement action against a global pharmaceutical supply arrangement that reached a national market. The findings show how antitrust scrutiny can reach international suppliers of key medicine ingredients.
CADE's findings rest on a five-year investigation that imposed more than 17 million reais (over $3 million) in fines across four companies and three individuals. The period of the cartel's operation is described only as roughly three decades, and the source does not break down fines by party.
The players
CADE (Conselho Administrativo de Defesa Econômica)
Brazil's administrative council for economic defense, the federal antitrust regulator responsible for investigating and sanctioning anticompetitive conduct in the country.
Alchem International
A pharmaceutical company held liable in the cartel case, named among the four firms sanctioned by Brazil's competition authority.
Alkaloids of India
An Indian pharmaceutical manufacturer held liable in the cartel case and sanctioned alongside its affiliate Alkaloids of Australia.
Alkaloids of Australia
An Australian affiliate of Alkaloids of India that was held liable and sanctioned in the cartel case.
The details
Brazil's competition authority found that the companies and individuals took part in a cartel covering the production and sale of an ingredient used in Buscopan, a widely sold abdominal pain medication. The sanctions followed a five-year probe that led to the liability findings against Alchem International, Alkaloids of India, Alkaloids of Australia, and Vital Laboratories.
Timeline
Roughly three decades: approximate duration of the global pharma cartel.
Five years: length of the CADE investigation that led to the findings.
November 4, 2026: CADE announced the sanctions against the companies and individuals.
Legal Context
Brazil's competition authority has increasingly pursued cartels that extend beyond domestic borders, and this case applies that approach to international suppliers of a common medication ingredient. The five-year timeline and multi-country defendant list show how such enforcement now routinely spans several national jurisdictions.
Buscopan is a widely used medication, so enforcement against cartels in its ingredient supply can bear on how the drug is priced and available. Readers who rely on the medicine may see the effects of this action in future supply and cost conditions, though the source does not describe immediate changes.
The takeaway
Cartels in pharmaceutical ingredients can operate for decades and affect markets far from their origin, and antitrust enforcement can reach multiple countries at once. Consumers and policymakers alike have a stake in how such conduct is detected and penalized.
Further reading
For related coverage of pharmaceutical enforcement actions, see Drug Crime.
Source note: This article includes information reported by Mlex.
